VCA sells stake of Vetstreet to Schein; Bayer charts mixed results for flea-and-tick portfolio; PetVivo shores up IP;

> VCA ($WOOF) said November 2 that it will sell a majority interest of its subsidiary Vetstreet, a software provider, to Henry Schein ($HSIC) for a recorded gain of $30 million to $35 million. Release

> Bayer announced that sales in its animal health division rose 2% year over year in the third quarter to €357 million ($394 million), helped by growth of its Seresto flea and tick products but hampered by a slight decline in its Advantage product line. Release

> PetVivo Holdings ($PETV) of Minneapolis announced it has been issued a European patent for its mucosal drug-delivery technology, which it is developing for both human and animal health. Release

> AmerisourceBergen ($ABC) announced that revenues in its fiscal fourth quarter grew 12% year over year to $35.5 billion and that its gross profit was up 15% to $1.1 billion, largely due to its acquisition of MWI Veterinary Supply. Release

> Anika Therapeutics ($ANIK), which has a portfolio of products that includes orthopedic therapies for horses, announced that its product revenues grew 8% year over year in the third quarter to $23.7 million and its net income jumped 36% to $8.4 million. Release

> Eli Lilly's ($LLY) Elanco has launched Interceptor Plus, a monthly chicken-flavored chewable tablet for dogs that protects against heartworm caused by Dirofilaria immitis, as well as several intestinal parasites. Release

> Jaguar Animal Health ($JAGX) announced that Cornell University College of Veterinary Medicine has completed a study of Neonorm Calf that supports the drug's ability to optimize the intestinal microbiome in preweaned dairy calves. Release

> France's Vetoquinol announced that its sales in the first 9 months of the year jumped 8.7% to €251.8 million ($277.9 million), thanks largely to a positive currency impact. Release

> Salix animal health expanded its recall of its Good 'n' Fun Beefhide Chicken Sticks dog treats because of possible Salmonella contamination. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…